Efficiency of metabolite therapy for neuro-vegetative disorders in children with acute respiratory infections

Objective. To evaluate the efficacy, tolerability, and safety of using a combination metabolite drug containing L-glutamic acid, glycine and L-cystine in comparison with basic therapy in the correction of neurovegetative disorders in children with acute respiratory infections. Subjects and methods. The investigation enrolled 53 patients aged 12 to 18 years with acute respiratory infections who had clinical manifestations of neurovegetative disorders. The patients were randomized into 2 groups: a study group (n = 27) and a control group (n = 26). The study group received the metabolite drug as part of combination therapy; the control group had the basic therapy. The duration of treatment was 30 days. All the patients underwent comprehensive assessment of the neurovegetative status at admission and at 1-month follow-up. Results. There were no patients with obvious asthenia in the study group at the follow-up, while the proportion of such patients was 3.8% in the comparison group. After the end of treatment, 70% of the patients in the study group were diagnosed with a predominance of sympathetic tone of the autonomic nervous system; these were only 42.3% in the comparison group (p < 0.05). At the same time, there was no obvious abnormal sympathetic regulation when the drug was used (unlike the comparison group where this was noted in 34.6% of cases; p < 0.01), suggesting that the functioning processes of the neuroregulatory system were restored. After treatment completion, the children in the study group had diminished central nervous break-down, enhanced working efficiency, improved performance, and lower-level anxiety. No adverse events or abnormal hemogram readings were recorded after completing the therapy cycle. Conclusion. The investigation showed the efficacy and safety of using the metabolite drug containing L-glutamic acid, glycine, and L-cystine in children with neurovegetative disorders in the presence of acute respiratory infections. The therapy contributed to the reduced severity of post-infection asthenia.

acute respiratory infections, neurovegetative status, children